Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...

The vehicle rolled up to the ambulance entrance at NorthBay Medical Center, and the frantic driver rushed to get medical help ...

Johnson & Johnson (NYSE:JNJ) is advancing psychedelic medicine with Spravato (esketamine), an FDA-approved nasal spray for treatment-resistant depression and acute suicidal ideation. Since its ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of sufficient efficacy, the drug and medical device maker said on Thursday.

A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.

The analyst equates COMP360 to Spravato 2.0. Johnson & Johnson’s JNJ Spravato (esketamine) is a nasal spray for TRD and major depressive disorder (MDD), selling over ~$1 billion annually.

MDMA, although not providing specific usage data, remains popular, especially in research for PTSD treatment. Ketamine has gained attention for its depression treatment potential, particularly with ...

The Reporter begins a three-day series today on Solano County’s response to the opioid and fentanyl crisis through law ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body.